Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
25
02
2022
received:
27
01
2022
accepted:
10
03
2022
pubmed:
22
3
2022
medline:
23
9
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function. In 216 patients with HCC who were consecutively treated with AtezoBev across 11 tertiary centers, we retrospectively evaluated treatment-related adverse events (trAEs) graded (G) according to Common Terminology Criteria for Adverse Events v5.0, including in the analysis all patients treated according to label (n = 202, 94%). We also assessed overall survival (OS), progression-free survival (PFS), overall response (ORR), and disease control rates (DCR) defined by Response Evaluation Criteria in Solid Tumors v1.1. Disease was mostly secondary to viral hepatitis, namely hepatitis C (n = 72; 36%) and hepatitis B infection (n = 35, 17%). Liver function was graded as Child-Pugh (CP)-A in 154 patients (76%) and CP-B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared with CP-A, patients with CP-B showed comparable rates of trAEs. Presence and grade of varices at pretreatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow-up of 9.0 months (95% CI, 7.8-10.1), median OS was 14.9 months (95% CI, 13.6-16.3), whereas median PFS was 6.8 months (95% CI, 5.2-8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes. This study confirms reproducible safety and efficacy of AtezoBev in routine practice. Patients with CP-B reported similar tolerability compared with CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.
Sections du résumé
BACKGROUND AND AIMS
Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function.
APPROACH AND RESULTS
In 216 patients with HCC who were consecutively treated with AtezoBev across 11 tertiary centers, we retrospectively evaluated treatment-related adverse events (trAEs) graded (G) according to Common Terminology Criteria for Adverse Events v5.0, including in the analysis all patients treated according to label (n = 202, 94%). We also assessed overall survival (OS), progression-free survival (PFS), overall response (ORR), and disease control rates (DCR) defined by Response Evaluation Criteria in Solid Tumors v1.1. Disease was mostly secondary to viral hepatitis, namely hepatitis C (n = 72; 36%) and hepatitis B infection (n = 35, 17%). Liver function was graded as Child-Pugh (CP)-A in 154 patients (76%) and CP-B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared with CP-A, patients with CP-B showed comparable rates of trAEs. Presence and grade of varices at pretreatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow-up of 9.0 months (95% CI, 7.8-10.1), median OS was 14.9 months (95% CI, 13.6-16.3), whereas median PFS was 6.8 months (95% CI, 5.2-8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes.
CONCLUSIONS
This study confirms reproducible safety and efficacy of AtezoBev in routine practice. Patients with CP-B reported similar tolerability compared with CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.
Identifiants
pubmed: 35313048
doi: 10.1002/hep.32468
pmc: PMC9790703
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Bevacizumab
2S9ZZM9Q9V
atezolizumab
52CMI0WC3Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1000-1012Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Cancer Rep (Hoboken). 2022 Feb;5(2):e1464
pubmed: 34114752
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
J Hepatol. 2021 Apr;74(4):931-943
pubmed: 33248171
Liver Cancer. 2020 Jan;9(1):93-104
pubmed: 32071913
Liver Cancer. 2021 Jun;10(3):240-248
pubmed: 34239810
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Hepatology. 2022 Oct;76(4):1000-1012
pubmed: 35313048
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Cancers (Basel). 2021 Jun 03;13(11):
pubmed: 34205099
Lancet Oncol. 2019 Apr;20(4):e200-e207
pubmed: 30942181
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Clin Pharmacokinet. 2019 Jul;58(7):835-857
pubmed: 30815848
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33028690
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Curr Opin Oncol. 2021 Jul 1;33(4):386-394
pubmed: 33867478
ESMO Open. 2020 Aug;5(4):
pubmed: 32847838
J Hepatol. 2016 Dec;65(6):1140-1147
pubmed: 27469901
Cancer. 2019 Sep 15;125(18):3234-3241
pubmed: 31154669
J Hepatol. 2021 Sep;75(3):600-609
pubmed: 34051329
Eur J Cancer. 2021 Nov;157:140-152
pubmed: 34508996
Cancers (Basel). 2020 Jul 10;12(7):
pubmed: 32664319
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Ann Oncol. 2013 Feb;24(2):406-411
pubmed: 23041587
Lancet Oncol. 2021 Jul;22(7):991-1001
pubmed: 34051880
Liver Int. 2022 Mar;42(3):674-681
pubmed: 34792284
Liver Int. 2021 Aug;41(8):1734-1743
pubmed: 34051060
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32868393
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
PLoS One. 2012;7(12):e49717
pubmed: 23284624